No connection

Search Results

BSX vs UNH

BSX
Boston Scientific Corporation
BULLISH
Price
$59.52
Market Cap
$88.46B
Sector
Healthcare
AI Confidence
75%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BSX
31.49
UNH
24.43
Forward P/E
BSX
15.26
UNH
16.08
P/B Ratio
BSX
3.64
UNH
3.11
P/S Ratio
BSX
4.41
UNH
0.66
EV/EBITDA
BSX
18.46
UNH
16.47

Profitability

Gross Margin
BSX
68.78%
UNH
18.53%
Operating Margin
BSX
19.69%
UNH
0.34%
Profit Margin
BSX
14.44%
UNH
2.69%
ROE
BSX
12.45%
UNH
12.54%
ROA
BSX
5.98%
UNH
3.9%

Growth

Revenue Growth
BSX
15.9%
UNH
12.3%
Earnings Growth
BSX
18.5%
UNH
-99.9%

Financial Health

Debt/Equity
BSX
0.49
UNH
0.82
Current Ratio
BSX
1.62
UNH
0.79
Quick Ratio
BSX
0.9
UNH
0.7

Dividends

Dividend Yield
BSX
--
UNH
2.73%
Payout Ratio
BSX
0.0%
UNH
65.99%

AI Verdict

BSX BULLISH

BSX presents a classic divergence between deteriorating technicals and strong fundamental growth. While the Piotroski F-Score of 4/9 indicates stable but not exceptional financial health, the company exhibits robust revenue (15.9%) and earnings (18.5%) growth. The stock is currently trading near its growth-based intrinsic value ($55.75) and significantly below analyst targets ($96.66), with a highly attractive PEG ratio of 0.66 suggesting undervaluation relative to growth. Despite a severe 6-month price decline, the consistent track record of earnings beats and a low Forward P/E (15.26) support a bullish long-term outlook.

Strengths
Strong double-digit revenue and earnings growth (YoY)
Highly attractive PEG ratio (0.66) indicating growth is underpriced
Consistent history of beating quarterly earnings estimates
Risks
Severe negative technical momentum (1Y change -36.4%, 6M change -40.4%)
High current P/E ratio (31.49) compared to historical value benchmarks
Lack of dividend yield provides no floor for income-seeking investors
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

BSX vs UNH: Head-to-Head Comparison

This page compares Boston Scientific Corporation (BSX) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile